NCT02654132 : Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab ( ELOQUENT-3)
Updated: Sep 27, 2022
ELOQUENT-3 trial
NCT02654132: Phase 2: An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
The purpose of this study is to determine if adding Elotuzumab to Pomalidomide and low-dose dexamethasone is a more effective treatment of relapsed and refractory multiple myeloma compared to pomalidomide and low-dose dexamethasone by itself.
Sponsor
Collaborators
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT02654132
Official Title: An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
First Posted : January 13, 2016
Click here for details on ClinicalTrials.gov
Drug: Elotuzumab
Drug: Pomalidomide
Drug: Dexamethasone
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
N Engl J Med;2018
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial
J Clin Oncol;2022 Aug
Location
United States, Georgia
United States, Illinois
United States, Indiana
United States, Massachusetts
United States, New York
United States, North Carolina
United States, Pennsylvania
United States, South Carolina
United States, Tennessee
United States, Utah
United States, Washington
Australia, Queensland
Canada, Ontario
Canada, Quebec
Europe
France
Germany
Greece
Italy
Japan
Netherlands
Poland
Spain